RxDoctor Payments Data

Alice Kennedy, MD

Retina Specialist · Conway, ARNPI 1396130555

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,215 of the $4,974 with a category attached, or 84.8%. It is spread thinly across 23 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,811 and has fallen 74.2% since, to $466 in 2025.

$4,974in general payments, 2019–2025

Across 105 payments — averaging $47.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$587
  • Eyepoint US, Inc.$498
  • Regeneron Healthcare Solutions, Inc.$466
  • Alimera Sciences, Inc.$362
  • Novartis$352
  • plus $2K from 17 others
$75,189in research payments, 2019–2025

Across 3 payments — averaging $25,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche TCRC, Inc.$75K

What the payments were for

  • Travel & lodging$66913%
  • Food & beverage$4,21585%
  • Entertainment$902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,693,434
Medicare patients
1,062
Services billed
26,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate139$5,696
Ketorolac Tromethamine25$649
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$506
Timolol Maleate38$462
Atropine Sulfate14$438
ValacyclovirValacyclovir Hcl11$275
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$241
ErythromycinErythromycin Base24$227
Latanoprost21$216
Brimonidine Tartrate13$54

Paid to pharmacies, not to this prescriber.

Other retina specialist in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →